AGTC to Participate in Upcoming Investor Conferences
Applied Genetic Technologies Corporation (AGTC), a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences. Key Events include:
- BTIG Biotechnology Conference - August 8, 2022, featuring CFO Jon Lieber.
- Wedbush PacGrow Healthcare Conference - August 9, 2022, with CEO Sue Washer and CFO Jon Lieber.
- H.C. Wainwright 2nd Annual Ophthalmology Conference - August 17, 2022, with an on-demand presentation by Sue Washer.
AGTC focuses on developing gene therapies for inherited retinal diseases and has strategic collaborations in optogenetics and CNS disorders.
- None.
- None.
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:
- BTIG Biotechnology Conference – New York (August 8, 2022)
Jon Lieber, Chief Financial Officer, will participate in one-on-one investor meetings.
- Wedbush PacGrow Healthcare Conference – Virtual (August 9, 2022)
Sue Washer, President and Chief Executive Officer, and Mr. Lieber will participate in one-on-one investor meetings.
- H.C. Wainwright 2nd Annual Ophthalmology Conference – Virtual (August 17, 2022)
A presentation with Ms. Washer will be available to view on-demand beginning on Wednesday, August 17 at 7:00 a.m. ET through the entirety of the conference.
The presentation can be accessed by visiting http://ir.agtc.com/events-and-presentations. Replays will be available on the Company's website following the events.
About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is designing and constructing critical gene therapy elements and bringing them together to develop customized therapies with the potential to address unmet patient needs. AGTC’s most advanced clinical programs in XLRP and ACHM CNGB3 leverage its technology platform to potentially improve vision for patients with inherited retinal diseases. Its preclinical programs build on the AGTC’s AAV manufacturing technology and scientific expertise. AGTC is advancing multiple pipeline candidates to address substantial unmet clinical needs in optogenetics, otology and CNS disorders, and has entered into strategic collaborations with companies including Bionic Sight, Inc., an innovator in the emerging field of optogenetics and retinal coding, and Otonomy, Inc., a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology.
IR Contact:
David Carey
Lazar FINN Partners
T: (212) 867-1768
david.carey@finnpartners.com
Corporate Contact:
Jonathan Lieber
Chief Financial Officer
Applied Genetic Technologies Corporation
T: (617) 843-5778
jlieber@agtc.com
FAQ
What events will AGTC participate in upcoming investor conferences?
Who will represent AGTC at the BTIG Biotechnology Conference?
When will AGTC's presentation be available during the H.C. Wainwright Conference?
What is the focus of AGTC's gene therapy development?
What strategic collaborations does AGTC have?
